Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study

Pain Med
May-June 2009
https://pubmed.ncbi.nlm.nih.gov/19453963/

Objective: Fibromyalgia is a chronic pain disorder that is characterized by diffuse musculoskeletal pain and sensitivity to mechanical stimulation. In this pilot clinical trial, we tested the effectiveness of low-dose naltrexone in treating the symptoms of fibromyalgia.

Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation

Expert Opin Investig Drugs
August 2007
https://www.ncbi.nlm.nih.gov/pubmed/17685875

Dissociation of POMC peptides after self-injury predicts responses to centrally acting opiate blockers

Am J Ment Retard
September 1997
https://www.ncbi.nlm.nih.gov/pubmed/?term=9327093

Effect of transcutaneous electrical stimulation on nociception and edema induced by peripheral serotonin

Int J Neurosc
July 2013
https://www.ncbi.nlm.nih.gov/pubmed/23336713

Oral naltrexone to enhance analgesia in patients receiving continuous intrathecal morphine for chronic pain: a randomized, double-blind, prospective pilot study

J Opioid Manag
May-Jun 2007
https://pubmed.ncbi.nlm.nih.gov/18027539/

A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis

J Mult Scler
September 2008
https://www.ncbi.nlm.nih.gov/pubmed/18728058

Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling

J Pain
August 2008
https://www.ncbi.nlm.nih.gov/pubmed/18468954

Oxycodone combined with opioid receptor antagonists: efficacy and safety

Expert Opin Drug Saf
May 2013
https://pubmed.ncbi.nlm.nih.gov/23534906/

Introduction: A mu receptor antagonist combined with oxycodone (OXY) may improve pain control, reduce physical tolerance and withdrawal, minimizing opioid-related bowel dysfunction and act as an abuse deterrent.

Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects

Eur J Pain
March 2011
https://www.ncbi.nlm.nih.gov/pubmed/20728384

Erythromelalgia in a Patient with Mast Cell Activation Syndrome: Response to Low Dose Naltrexone

Skin
08 May 2019
https://jofskin.org/index.php/skin/article/view/722

Erythromelalgia is a rare condition that may be associated with a variety of underlying conditions and is often refractory to therapy. We report a case of a patient with mast cell activation syndrome who developed erythromelalgia and responded to low dose naltrexone.